Emily Chen is the Associate Director of Business Development at Zymeworks, a clinical stage biotechnology company for difficult-to-treat diseases. In this role, she focuses on forging partnerships and strategic initiatives within the oncology sector, emphasizing ADC pipeline advancements. Prior to joining Zymeworks, her BD tenure also spans roles at Atreca, where she led ADC and Asia-focused partnership strategies, and Simcere, driving significant in-licensing deals in oncology for Greater China rights. Emily’s cross-market expertise in the US and Asia demonstrates a solid track record in business development, alliance management, and strategic negotiations. Emily holds a Ph.D. in Medicinal Chemistry and Molecular Pharmacology from Purdue University and a Bachelor of Science degree in Pharmacology and Toxicology from University of Wisconsin-Madison.